Innate Pharma, Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.3M
Doctors Paid
135
Transactions
299
2021 Total
$172,701
Payment Breakdown by Category
Research$3.3M (97.8%)
Consulting$29,136 (0.9%)
Food & Beverage$3,464 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 170 | 97.8% |
| Honoraria | $39,750 | 20 | 1.2% |
| Consulting Fee | $29,136 | 9 | 0.9% |
| Food and Beverage | $3,464 | 100 | 0.1% |
Payments by Type
Research
$3.3M
170 transactions
General
$72,350
129 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | $2.2M | 0 | 88 |
| An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma | $440,121 | 1 | 24 |
| A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti) and Rituximab (Rituxan) for Relapsed Hairy Cell Leukemia | $212,080 | 0 | 2 |
| A Phase I Study of the Anti-C5aR, Avdoralimab (IPH5401), in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors | $155,954 | 0 | 23 |
| A phase-I study of the anti-C5aR, IPH5401, in combination with the anti-PDL-1, durvalumab, in patients with selected advanced solid tumors | $150,989 | 6 | 20 |
| Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | $129,531 | 0 | 13 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Medical Oncology | $140,001 | 19 | $7,368 |
| Hematology & Oncology | $40,770 | 72 | $566.25 |
| Internal Medicine | $21,440 | 18 | $1,191 |
| Dermatopathology | $14,848 | 1 | $14,848 |
| Hematology | $11,868 | 13 | $912.91 |
| Specialist | $1,268 | 6 | $211.30 |
| Dermatology | $483.33 | 1 | $483.33 |
| Hospice and Palliative Medicine | $36.91 | 2 | $18.46 |
| Gynecologic Oncology | $19.03 | 1 | $19.03 |
| Pediatrics | $12.35 | 1 | $12.35 |
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Stephan Rosenfeld, M.d, M.D | Hematology & Oncology | Fayetteville, AR | $12.44 | $0 |
| Padmaja Venuturumilli, Md, MD | Pediatrics | Royal Oak, MI | $12.35 | $0 |
| Richard Zuniga, Md, MD | Hematology & Oncology | Babylon, NY | $12.02 | $0 |
| Mrs. Lynsay Brautnick, M.d, M.D | Hematology & Oncology | Fayetteville, AR | $11.82 | $0 |
| Mohit Narang, M.d, M.D | Specialist | Owing Mills, MD | $11.75 | $0 |
| Dr. Miriam Atkins, M.d, M.D | Hematology & Oncology | Augusta, GA | $11.60 | $0 |
| Dr. Robert Horowitz, Md, MD | Medical Oncology | Ithaca, NY | $11.23 | $0 |
| Sudarshan Doddabele, Md, MD | Hematology & Oncology | Knoxville, TN | $11.19 | $0 |
| Dr. Richard Gordon, D.o, D.O | Specialist | Voorhees, NJ | $11.17 | $0 |
| Dr. Trina Poretta, D.o, D.O | Specialist | Voorhees, NJ | $11.17 | $0 |
About Innate Pharma, Inc
Innate Pharma, Inc has made $3.3M in payments to 135 healthcare providers, recorded across 299 transactions in the CMS Open Payments database. In 2021, the company paid $172,701. The top product by payment volume is Lumoxiti ($435,419).
Payments were distributed across 10 medical specialties. The top specialty by payment amount is Medical Oncology ($140,001 to 19 doctors).
Payment categories include: Food & Beverage ($3,464), Consulting ($29,136), Research ($3.3M).
Innate Pharma, Inc is associated with 1 products in the CMS Open Payments database.